FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308977900> ?p ?o ?g. }

• W4308977900 endingPage "vii211" @default.
• W4308977900 startingPage "vii211" @default.
• W4308977900 abstract "Abstract Diffuse midline gliomas (DMGs), including those of the pons (diffuse intrinsic pontine glioma - DIPG), are pediatric CNS tumors recognized as the most lethal of all children’s cancers. Palliative radiotherapy remains the only approved treatment, with survival just 9-11 months post-diagnosis. The brain-penetrant small molecule therapy, ONC201, shows preclinical and emerging efficacy in early-stage clinical trials. However, patients invariably develop resistance, with some patients and models completely refractory to treatment. Using a powerful combination of pharmacology, proteomics, genomics, epigenetics, in vitro and in vivo modeling, across ten international laboratories, we have uncovered mechanisms underpinning resistance to ONC201. We find ONC201 elicits antagonism of the Dopamine receptor D2 (DRD2), whilst also causing mitochondrial degradation through potent agonism of the mitochondrial protease CLPP. This drives proteolysis of the electron transport chain (ETC) proteins including Succinate dehydrogenase A (SDHA) and the critical mitochondrial tricarboxylic acid (TCA) cycle regulator, Isocitrate dehydrogenase 3B (IDH3B). Loss of TCA activity reduces α-ketoglutarate and inhibits lysine demethylation, increasing methylation of H3K4me3 and H3K27me3, thus, altering the epigenome of DIPG. Mitochondrial disruption elicited redox-activated RAS-PI3K/AKT signaling, counteracted using the PI3K/AKT inhibitor paxalisib. The combination of ONC201 and paxalisib synergistically extended survival of two aggressive DIPG PDX models (SU-DIPG-VI vehicle=73 vs. combination=100-days, p=0.0027; SF8626 vehicle=36 vs. combination=43-days, p=0.0002). Compassionate access to this combination (n=2 patients; immediately post-RT and following re-RT) resulted in dramatic reductions in tumor volume, extending overall survival for the patient at diagnosis and the patient at progression (e.g., MR axial diagnosis scan = 1554 mm2, following twelve months on the combination, current tumor volume = 464 mm2 (~70% reduction), patient remains in progression free survival, 15 months since diagnosis). The clinical utility of our preclinical data is currently under investigation in the PNOC022 clinical trial (NCT05009992)." @default.
• W4308977900 created "2022-11-20" @default.
• W4308977900 creator A5000958028 @default.
• W4308977900 creator A5001293585 @default.
• W4308977900 creator A5002062212 @default.
• W4308977900 creator A5003177738 @default.
• W4308977900 creator A5007562225 @default.
• W4308977900 creator A5013078515 @default.
• W4308977900 creator A5022374534 @default.
• W4308977900 creator A5025787557 @default.
• W4308977900 creator A5027481087 @default.
• W4308977900 creator A5030139231 @default.
• W4308977900 creator A5030956680 @default.
• W4308977900 creator A5034466746 @default.
• W4308977900 creator A5034496059 @default.
• W4308977900 creator A5038979693 @default.
• W4308977900 creator A5041419820 @default.
• W4308977900 creator A5041455943 @default.
• W4308977900 creator A5044799575 @default.
• W4308977900 creator A5050535456 @default.
• W4308977900 creator A5059278796 @default.
• W4308977900 creator A5062436617 @default.
• W4308977900 creator A5066009774 @default.
• W4308977900 creator A5066498990 @default.
• W4308977900 creator A5070558304 @default.
• W4308977900 creator A5071718921 @default.
• W4308977900 creator A5076372373 @default.
• W4308977900 creator A5081047170 @default.
• W4308977900 creator A5081734192 @default.
• W4308977900 creator A5082031383 @default.
• W4308977900 creator A5083568102 @default.
• W4308977900 creator A5084156179 @default.
• W4308977900 creator A5084305193 @default.
• W4308977900 creator A5085515145 @default.
• W4308977900 creator A5085683988 @default.
• W4308977900 creator A5087383285 @default.
• W4308977900 creator A5091771182 @default.
• W4308977900 date "2022-11-01" @default.
• W4308977900 modified "2023-10-16" @default.
• W4308977900 title "EXTH-12. PRECLINICAL AND CASE STUDY EXAMINATION OF THE COMBINATION OF THE CLPP AGONIST ONC201 WITH THE PI3K/AKT INHIBITOR PAXALISIB FOR THE TREATMENT OF DIFFUSE MIDLINE GLIOMA" @default.
• W4308977900 doi "https://doi.org/10.1093/neuonc/noac209.811" @default.
• W4308977900 hasPublicationYear "2022" @default.
• W4308977900 type Work @default.
• W4308977900 citedByCount "0" @default.
• W4308977900 crossrefType "journal-article" @default.
• W4308977900 hasAuthorship W4308977900A5000958028 @default.
• W4308977900 hasAuthorship W4308977900A5001293585 @default.
• W4308977900 hasAuthorship W4308977900A5002062212 @default.
• W4308977900 hasAuthorship W4308977900A5003177738 @default.
• W4308977900 hasAuthorship W4308977900A5007562225 @default.
• W4308977900 hasAuthorship W4308977900A5013078515 @default.
• W4308977900 hasAuthorship W4308977900A5022374534 @default.
• W4308977900 hasAuthorship W4308977900A5025787557 @default.
• W4308977900 hasAuthorship W4308977900A5027481087 @default.
• W4308977900 hasAuthorship W4308977900A5030139231 @default.
• W4308977900 hasAuthorship W4308977900A5030956680 @default.
• W4308977900 hasAuthorship W4308977900A5034466746 @default.
• W4308977900 hasAuthorship W4308977900A5034496059 @default.
• W4308977900 hasAuthorship W4308977900A5038979693 @default.
• W4308977900 hasAuthorship W4308977900A5041419820 @default.
• W4308977900 hasAuthorship W4308977900A5041455943 @default.
• W4308977900 hasAuthorship W4308977900A5044799575 @default.
• W4308977900 hasAuthorship W4308977900A5050535456 @default.
• W4308977900 hasAuthorship W4308977900A5059278796 @default.
• W4308977900 hasAuthorship W4308977900A5062436617 @default.
• W4308977900 hasAuthorship W4308977900A5066009774 @default.
• W4308977900 hasAuthorship W4308977900A5066498990 @default.
• W4308977900 hasAuthorship W4308977900A5070558304 @default.
• W4308977900 hasAuthorship W4308977900A5071718921 @default.
• W4308977900 hasAuthorship W4308977900A5076372373 @default.
• W4308977900 hasAuthorship W4308977900A5081047170 @default.
• W4308977900 hasAuthorship W4308977900A5081734192 @default.
• W4308977900 hasAuthorship W4308977900A5082031383 @default.
• W4308977900 hasAuthorship W4308977900A5083568102 @default.
• W4308977900 hasAuthorship W4308977900A5084156179 @default.
• W4308977900 hasAuthorship W4308977900A5084305193 @default.
• W4308977900 hasAuthorship W4308977900A5085515145 @default.
• W4308977900 hasAuthorship W4308977900A5085683988 @default.
• W4308977900 hasAuthorship W4308977900A5087383285 @default.
• W4308977900 hasAuthorship W4308977900A5091771182 @default.
• W4308977900 hasBestOaLocation W43089779001 @default.
• W4308977900 hasConcept C11960822 @default.
• W4308977900 hasConcept C2778227246 @default.
• W4308977900 hasConcept C502942594 @default.
• W4308977900 hasConcept C55493867 @default.
• W4308977900 hasConcept C62478195 @default.
• W4308977900 hasConcept C71924100 @default.
• W4308977900 hasConcept C75217442 @default.
• W4308977900 hasConcept C86554907 @default.
• W4308977900 hasConcept C86803240 @default.
• W4308977900 hasConcept C98274493 @default.
• W4308977900 hasConceptScore W4308977900C11960822 @default.
• W4308977900 hasConceptScore W4308977900C2778227246 @default.
• W4308977900 hasConceptScore W4308977900C502942594 @default.
• W4308977900 hasConceptScore W4308977900C55493867 @default.
• W4308977900 hasConceptScore W4308977900C62478195 @default.
• W4308977900 hasConceptScore W4308977900C71924100 @default.
• W4308977900 hasConceptScore W4308977900C75217442 @default.

• next